SCHEMBL5883708

SCHEMBL5883708

COC(=O)CCCCC=C(C)C

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.60
LMNA P02545 2/20 0.60
TSHR P16473 3/20 0.56
EPHX2 P34913 1/20 0.46
RECQL P46063 1/20 0.45
TBXAS1 P24557 1/20 0.44
ALOX15 P16050 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ATM Q13315 1/20 0.39
MGAM O43451 1/20 0.39
GAA P10253 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
ALOX5 P09917 1/20 0.39
OXER1 Q8TDS5 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17520245 0.98 LMNA (0.63) ALDH1A1LMNATSHREPHX2RECQL
SCHEMBL27948186 0.94 TSHR (0.58) ALDH1A1LMNATSHREPHX2TBXAS1
SCHEMBL6763939 0.91 KMT2A (0.53) ALDH1A1LMNAALOX15KMT2A
SCHEMBL6763941 0.91 KMT2A (0.53) ALDH1A1LMNAALOX15KMT2A
SCHEMBL10890107 0.88 ALDH1A1 (0.53) ALDH1A1LMNATSHREPHX2RECQL
SCHEMBL10889301 0.88 ALDH1A1 (0.53) ALDH1A1LMNATSHREPHX2RECQL
SCHEMBL10892227 0.88 ALDH1A1 (0.53) ALDH1A1LMNATSHREPHX2RECQL
SCHEMBL1360794 0.85 ALDH1A1 (0.49) ALDH1A1LMNATSHREPHX2RECQL
SCHEMBL493731 0.85 TSHR (0.55) ALDH1A1LMNATSHRALOX15KDM4E
SCHEMBL10887765 0.82 ALDH1A1 (0.50) ALDH1A1LMNATSHREPHX2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180037843-A1 PERFUME SYSTEMS PROCTER & GAMBLE (US) 2018-02-08 US claimed
EP-2723841-B1 PERFUME SYSTEMS PROCTER & GAMBLE (US) 2017-01-04 EP claimed
US-20160186093-A1 PERFUME SYSTEMS PROCTER & GAMBLE (US) 2016-06-30 US claimed
US-9309487-B2 Perfume systems THE PROCTER & GAMBLE COMPANY (US) 2016-04-12 US claimed
US-20140378360-A1 PERFUME SYSTEMS PROCTER & GAMBLE (US) 2014-12-25 US claimed
EP-2723841-A1 PERFUME SYSTEMS The Procter and Gamble Company (US) 2014-04-30 EP claimed
US-20120329696-A1 PERFUME SYSTEMS PROCTER & GAMBLE COMPANY, THE 2012-12-27 US claimed
WO-2012177357-A1 PERFUME SYSTEMS THE PROCTER & GAMBLE COMPANY (US) 2012-12-27 WO claimed
US-20180037843-A1 PERFUME SYSTEMS PROCTER & GAMBLE (US) 2018-02-08 US disclosed
US-20180037843-A1 PERFUME SYSTEMS PROCTER & GAMBLE (US) 2018-02-08 US disclosed
US-20180037843-A1 PERFUME SYSTEMS PROCTER & GAMBLE (US) 2018-02-08 US disclosed
US-9822327-B2 Perfume systems THE PROCTER & GAMBLE COMPANY (US) 2017-11-21 US disclosed
US-9822327-B2 Perfume systems THE PROCTER & GAMBLE COMPANY (US) 2017-11-21 US disclosed
US-9822327-B2 Perfume systems THE PROCTER & GAMBLE COMPANY (US) 2017-11-21 US disclosed
US-20120329696-A1 PERFUME SYSTEMS PROCTER & GAMBLE COMPANY, THE 2012-12-27 US disclosed
WO-2012177357-A1 PERFUME SYSTEMS THE PROCTER & GAMBLE COMPANY (US) 2012-12-27 WO disclosed
US-20120329696-A1 PERFUME SYSTEMS PROCTER & GAMBLE COMPANY, THE 2012-12-27 US disclosed
US-20120329696-A1 PERFUME SYSTEMS PROCTER & GAMBLE COMPANY, THE 2012-12-27 US disclosed
US-7091357-B2 Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) 2006-08-15 US disclosed
US-20030225142-A1 Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225142-A1 Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies CHRNA4, CHRNA2, CHRNA5 ALDH1A1 923/4885LMNA 3674/4885TSHR 340/4885
US-20180037843-A1 PERFUME SYSTEMS TRPA1, PORCN, PLIN5 ALDH1A1 1292/4885LMNA 2632/4885TSHR 4787/4885
US-20120329696-A1 PERFUME SYSTEMS TRPA1, PORCN, PLIN5 ALDH1A1 1292/4885LMNA 2632/4885TSHR 4787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.